Nexa is expanding from semiconductor automation into bio-automation. Using its EFEM tech supplied to Samsung, the firm now provides autonomous analytical platforms. Its bio-division is currently focused on developing high-quality manufacturing equipment for Antibody-Drug Conjugates (ADCs).

To meet the rising demand for GMP-compliant ADC manufacturing, we are developing an automated system using semiconductor and MEMS tech. It features continuous processing and ML algorithms to enable real-time monitoring of critical quality attributes like purity and mixing uniformity.